<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465530</url>
  </required_header>
  <id_info>
    <org_study_id>10553</org_study_id>
    <nct_id>NCT00465530</nct_id>
  </id_info>
  <brief_title>Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children</brief_title>
  <official_title>Safety and Efficacy of Once Daily Intranasal Gentamycin Irrigation Versus Saline in the Treatment of Pediatric Chronic Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Julie Wei, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy children may develop symptoms of chronic sinusitis such as chronic cough, chronic
      runny nose, nasal congestion, even headaches. Such symptoms may persist long after the child
      gets over other symptoms of a cold and commonly result in the prescription of oral
      antibiotics. The purpose of this study is to evaluate whether using saline alone or saline
      plus an antibiotic (gentamycin) to irrigate the nose directly once a day for 6 weeks is
      effective and safe for the treatment of the above named symptoms. Computerized axial
      tomography (CAT) scans and quality of life surveys will be used to compare the health of the
      sinuses before and after treatment, and scored to determine which of the two treatments,
      saline alone or saline with gentamycin, is more effective in the treatment of this condition.
      The study hypothesis is that intranasal saline irrigation will work as well as saline plus
      gentamycin, and that majority of the patients will experience significant improvement after a
      6 week treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the pediatric population, rhinosinusitis is a common concern resulting frequently in the
      frequent and unsuccessful prescription of systemic oral antibiotic therapy. Children
      typically experience an estimated 6-8 upper respiratory illnesses per year, usually viral,
      and only 13% are estimated to result in true sinusitis. True and chronic sinusitis, if not
      adequately treated, may result in long term symptoms including nasal airway obstruction,
      nasal congestion, persistent mucopurulent rhinorrhea, daytime and nocturnal cough, headaches,
      daytime fatigue, and even exacerbation or poor control of underlying asthma. A child's
      quality of life can be severely impacted as is their caretaker's due to days of missed
      school, frequency of doctor visits and courses of oral antibiotic therapy prescribed for the
      above mentioned symptoms, which ultimately result in the development of resistant organisms
      in addition to potential negative side effects associated with systemic oral antibiotic use.

      Intranasal saline irrigation is underutilized in the pediatric population, most likely due to
      the presumption that children will not cooperate nor tolerate the act of irrigation. Saline
      irrigation of the nose is an inexpensive and generally well tolerated treatment with very
      little side effects or risks. Rigorous data regarding the efficacy of saline irrigation has
      become more available in this past decade, with most studies demonstrating a clear
      improvement in patient quality of life as measured by various study instruments or outcome
      surveys.

      In our protocol, patients will be randomized to receive either saline alone or saline plus
      gentamycin in the solution form for nasal irrigation once daily for a six week treatment
      period. Weekly phone calls will be made to check for possible adverse events while patients
      are on treatment, and at the end of the treatment period another CAT scan will be performed
      to assess the status of the sinuses. Overall improvement will be determined based on the
      sinus status on the second CAT scan as well as the quality of life survey filled out by
      parents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Computed Tomography (CT) Score After Treatment</measure>
    <time_frame>Change from Baseline to 6 Weeks</time_frame>
    <description>Change in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Overall Quality of Life</measure>
    <time_frame>3 Weeks to Follow-Up (7 Weeks)</time_frame>
    <description>Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Overall Quality of Life</measure>
    <time_frame>Baseline to 3 Weeks</time_frame>
    <description>Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline plus Gentamycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intranasal Saline</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamycin</intervention_name>
    <description>Intranasal irrigation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children age 4-17

          -  History of &quot;Recurrent&quot; or &quot;Chronic Sinusitis&quot;

               -  Definition: History must include &gt; 3 months of any or a combination of the
                  following symptoms:

               -  Nasal congestion/nasal airway obstruction

               -  Rhinorrhea/Nasal discharge

               -  Persistent cough (daytime)

               -  Postnasal drip

               -  Headache

               -  Facial pain

               -  Foul breath

               -  Intermittent fever

          -  Caregiver (proxy responsible) able to read and understand English

          -  Has had at least 3 courses or a total of 21 days of oral antibiotic therapy for above
             symptoms in the previous 3 months

          -  Child has a CT scan of the coronal sinus without contrast within two months prior to
             visit date, which demonstrates and opacification of a single or multiple, ipsilateral
             or bilateral sinuses.

        Exclusion Criteria:

          -  Inability of caregiver to read and understand English

          -  Mental retardation, cognitive impairment, or developmental delay

          -  History of cystic fibrosis

          -  History of immotile cilia syndrome

          -  History of immune suppression/immune compromise

          -  CT scan within past 4 weeks available for review at time of clinic visit which is
             entirely negative for evidence of sinus disease plus complete absence of any of the
             above symptoms

          -  History of endoscopic sinus surgery

          -  History of patient's inability to tolerate attempted nasal irrigation in the past 6
             months

          -  History of recent use of gentamycin intranasal irrigation or saline irrigation within
             the past 3 months

          -  History of presence of nasal polyposis

          -  History of allergic reaction of any kind to intravenous gentamycin or aminoglycosides
             in past medical history (for treatment of any infections)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie L Wei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas MedWest</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <zip>66217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <results_first_submitted>December 11, 2012</results_first_submitted>
  <results_first_submitted_qc>April 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2013</results_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Julie Wei, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline Plus Gentamycin (Once Daily, 40 mL to Each Nostril)</title>
        </group>
        <group group_id="P2">
          <title>Saline (Once Daily, 40 mL to Each Nostril)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline Plus Gentamycin (Once Daily, 40 mL to Each Nostril)</title>
        </group>
        <group group_id="B2">
          <title>Saline (Once Daily, 40 mL to Each Nostril)</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Computed Tomography (CT) Score After Treatment</title>
        <description>Change in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification.</description>
        <time_frame>Change from Baseline to 6 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline (Once Daily, 40 mL to Each Nostril)</title>
          </group>
          <group group_id="O2">
            <title>Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Computed Tomography (CT) Score After Treatment</title>
          <description>Change in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left maxillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.64" spread=".63"/>
                    <measurement group_id="O2" value="-.63" spread=".5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right maxillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.5" spread=".65"/>
                    <measurement group_id="O2" value="-.5" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left anterior ethmoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.79" spread=".7"/>
                    <measurement group_id="O2" value="-1.06" spread=".68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right anterior ethmoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.79" spread=".8"/>
                    <measurement group_id="O2" value="-.63" spread=".81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left posterior ethmoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.57" spread=".65"/>
                    <measurement group_id="O2" value="-.81" spread=".66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right posterior ethmoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.64" spread=".63"/>
                    <measurement group_id="O2" value="-.75" spread=".68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left sphenoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.43" spread=".65"/>
                    <measurement group_id="O2" value="-.5" spread=".73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right sphenoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.5" spread=".65"/>
                    <measurement group_id="O2" value="-.5" spread=".73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left frontal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.89" spread=".78"/>
                    <measurement group_id="O2" value="-.56" spread=".53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right frontal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.8" spread=".63"/>
                    <measurement group_id="O2" value="-.22" spread=".44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left OMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.03"/>
                    <measurement group_id="O2" value="-1.25" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right OMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.86" spread="1.29"/>
                    <measurement group_id="O2" value="-.88" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score, left</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.07" spread="3.25"/>
                    <measurement group_id="O2" value="-4.56" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score, right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.86" spread="3.11"/>
                    <measurement group_id="O2" value="-3.38" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Overall Quality of Life</title>
        <description>Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.</description>
        <time_frame>Baseline to 3 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline (Once Daily, 40 mL to Each Nostril)</title>
          </group>
          <group group_id="O2">
            <title>Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Overall Quality of Life</title>
          <description>Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="1.99"/>
                    <measurement group_id="O2" value="2.06" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Overall Quality of Life</title>
        <description>Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.</description>
        <time_frame>3 Weeks to Follow-Up (7 Weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline (Once Daily, 40 mL to Each Nostril)</title>
          </group>
          <group group_id="O2">
            <title>Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Overall Quality of Life</title>
          <description>Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".69" spread="1.75"/>
                    <measurement group_id="O2" value="1.38" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline Plus Gentamycin (Once Daily, 40 mL to Each Nostril)</title>
        </group>
        <group group_id="E2">
          <title>Saline (Once Daily, 40 mL to Each Nostril)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Symptoms of Allergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Acute otitis media (AOM)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Poison Ivy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Julie Wei</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 588-6664</phone>
      <email>jwei@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

